FOXO TECHNOLOGIES INC. Equity Method Investment, Other than Temporary Impairment
FOXO TECHNOLOGIES INC. (FOXO) reported Equity Method Investment, Other than Temporary Impairment of $1.31 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Income Statement › Other Income
us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment · last filed 2023-05-11
- FOXO TECHNOLOGIES INC. equity method investment, other than temporary impairment for the quarter ending 2022-03-31 was $7.43M.
- FOXO TECHNOLOGIES INC. equity method investment, other than temporary impairment for fiscal 2022 was $1.31M, a 93.98% decline from fiscal 2021.
- FOXO TECHNOLOGIES INC. equity method investment, other than temporary impairment for fiscal 2021 was $21.70M.
| Period end | Equity Method Investment, Other than Temporary Impairment 3 month | Equity Method Investment, Other than Temporary Impairment 12 month |
|---|---|---|
| 2022-12-31 | $1.31M 10-K · filed 2023-03-31 | |
| 2022-03-31 | $7.43M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $21.70M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |